Ocular Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
The Ocular Hypertension pipeline market research report provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.
Ocular Hypertension Pipeline Drugs Market by Key Targets
Some of the targets of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A. Prostaglandin F2 Alpha Receptor has the highest number of pipeline products.
Ocular Hypertension Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Ocular Hypertension Pipeline Drugs Market
Some of the mechanisms of action of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist.
Ocular Hypertension Pipeline Drugs Market, by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Ocular Hypertension Pipeline Drugs Market
The routes of administration in the Ocular Hypertension pipeline drugs market are ophthalmic, intraocular, intravitreal, intravenous, oral, parenteral, buccal, conjunctival, intraarticular, and nasal.
Ocular Hypertension Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Ocular Hypertension Pipeline Drugs Market
The molecule types in the Ocular Hypertension pipeline drugs market are small molecule, gene therapy, antisense RNAi oligonucleotide, cell therapy, and protein. Small molecule has the highest number of pipeline products.
Ocular Hypertension Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Ocular Hypertension Pipeline Drugs Market Companies
Some of the key companies in the Ocular Hypertension pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa.
Ocular Hypertension Pipeline Drugs Market, by Key Companies
To know more about key companies, download a free report sample
Market Report Overview
| Key Targets | Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A |
| Key Mechanisms of Action | Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist |
| Key Routes of Administration | Ophthalmic, Intraocular, Intravitreal, Intravenous, Oral, Parenteral, Buccal, Conjunctival, Intraarticular, and Nasal |
| Key Molecule Types | Small Molecule, Gene Therapy, Antisense Rnai Oligonucleotide, Cell Therapy, and Protein |
| Key Companies | NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
- Reviews of pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
- Evaluation of Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Ocular Hypertension (Ophthalmology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology)
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline
AbbVie Inc
Aerie Pharmaceuticals Inc
Angelini Spa
Betaliq Inc
Chong Kun Dang Pharmaceutical Corp
D. Western Therapeutics Institute Inc
Future Medicine Co Ltd
Glaukos Corp
Graybug Vision Inc
Ikarovec Ltd
Jenivision Inc
Kowa Co Ltd
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee's Pharmaceutical Holdings Ltd
MediPrint Ophthalmics Inc
Neurim Pharmaceuticals Ltd
NicOx SA
Noveome Biotherapeutics Inc
Ocular Therapeutix Inc
pH Pharma Co Ltd
Qlaris Bio Inc
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Shenzhen Hornetcorn Bio-technology Company Ltd
Skye Bioscience Inc
Sun Pharma Advanced Research Company Ltd
Sun Pharmaceutical Industries Ltd
Sustained Nano Systems LLC
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
ViSci Ltd
Visus Therapeutics Inc
Whitecap Biosciences LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Ocular Hypertension pipeline drugs market?
Some of the targets of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A.
-
What are the mechanisms of action of the Ocular Hypertension pipeline drugs market?
Some of the mechanisms of action of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist.
-
What are the routes of administration in the Ocular Hypertension pipeline drugs market?
The routes of administration in the Ocular Hypertension pipeline drugs market are ophthalmic, intraocular, intravitreal, intravenous, oral, parenteral, buccal, conjunctival, intraarticular, and nasal.
-
What are the molecule types in the Ocular Hypertension pipeline drugs market?
The molecule types in the Ocular Hypertension pipeline drugs market are small molecule, gene therapy, antisense RNAi oligonucleotide, cell therapy, and protein.
-
Which are the key companies in the Ocular Hypertension pipeline drugs market?
Some of the key companies in the Ocular Hypertension pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Ophthalmology reports